Počet záznamov: 1
omalizumab
SYS d000069444 LBL 00000nz--a2200181n--4500 005 20250606221746.9 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D12.776.124.486.485.114.071.500 065 $a D12.776.124.486.485.114.224.060.844 065 $a D12.776.124.790.651.114.071.500 065 $a D12.776.124.790.651.114.224.060.844 065 $a D12.776.377.715.548.114.071.500 065 $a D12.776.377.715.548.114.224.200.844 066 $a 01 $c 03 150 $a omalizumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 550 $7 sllk_us_auth*d018926 $Y Anti-Allergic Agents $w P $a antialergiká 550 $7 sllk_us_auth*d018927 $Y Anti-Asthmatic Agents $w P $a antiastmatiká 665 $a 2016 (2001) $2 eng 680 9-
$i An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA. $2 eng 750 -2
$a Omalizumab $2 eng 980 $x M
Počet záznamov: 1